世界の医療・医薬品産業レポート

TOP  >  疾患別治験・パイプラインレポート  >  遺伝子  >  原発性免疫不全 (PID) - パイプラインレビュー 2018年上半期

原発性免疫不全 (PID) - パイプラインレビュー 2018年上半期
Primary Immune Deficiency (PID) - Pipeline Review, H1 2018

レポートタイトル 原発性免疫不全 (PID) - パイプラインレビュー 2018年上半期
出版社名 Global Markets Direct
発刊日 2018-02-27
体裁 PDF / 87 ページ
シングルユーザ価格 US$ 2,000
レポート分類 疾患別治験・パイプラインレポート
地域 グローバル
領域 遺伝子
疾患名 原発性免疫不全 (PID)
薬剤名 -
企業名 -
備考 ※ ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※ 本レポートは、英文です。PDF(電子媒体)での納品となります。

レポート概要

このレポートは、世界の主要国における上記疾患の治療薬開発についての包括的情報、さまざまな開発ステージでの比較分析、薬剤ターゲット、作用機序(MoA)、投与方法(RoA)、分子タイプ別の薬剤評価、および最新情報、ニュースやプレスリリースなどを提供します。
また、上記疾患における治療薬開発に関わる主要企業概要、開発後期および中止プロジェクトの特集などを提供します。


Global Market Direct社のレポートは、20の治療領域および3000もの適応症をカバーした治験薬を特集しています。
本レポートは、Global Market Direct社独自のデータベース、企業/大学ウェブサイト、SEC書類、企業や大学のウェブサイトからのプレゼンテーションやプレスリリース、および業界特有の第三者情報源、自社分析を基にしたデータや情報を盛り込んでいます。


本レポートは、意思決定能力を高め、競争上の優位性を得るための効果的な戦略を立案するのに役立ちます。
ファーストインクラスやベストインクラス製品を作り出すため、新たなターゲットやMOAを特定することにより、R&Dパイプラインを強化します。


注)本レポートの一部のセクションは、該当疾患におけるデータの可用性や妥当性に基づいて、削除または変更される場合があります。

目次

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Primary Immune Deficiency (PID) - Overview
Primary Immune Deficiency (PID) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Primary Immune Deficiency (PID) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Primary Immune Deficiency (PID) - Companies Involved in Therapeutics Development
ADMA Biologics Inc
Biotest AG
Casebia Therapeutics
Genethon SA
GigaGen Inc
GlaxoSmithKline Plc
Green Cross Corp
Leadiant Biosciences Inc
Novartis AG
Octapharma AG
ProMetic Life Sciences Inc
Sangamo Therapeutics Inc
Shire Plc
Taiga Biotechnologies Inc
Therapure Biopharma Inc
UCB SA
X4 Pharmaceuticals Inc
Primary Immune Deficiency (PID) - Drug Profiles
aldesleukin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody for Primary Immune Deficiency Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BT-595 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for RAG-Deficient Severe Combined Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elapegademase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for X-Linked SCID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Adenosine Deaminase for Adenosine Deaminase Deficiency Related SCID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate IL2RG for SCID-X1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate IL2RG for X-Linked SCID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hyaluronidase (recombinant, human) + immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OTL-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RI-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPL-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seletalisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CXCL12 for Primary Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Hematological Disorders and Primary Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Severe Combined Immunodeficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for X-Linked SCID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for X-Linked SCID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate Artemis for Radiosensitive Severe Combined Immunodeficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate Artemis for Severe Combined Immune Deficiency - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate IL-2 Gamma Receptor for SCID-X1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate IL-2 Gamma Receptor for X-Linked SCID - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Strimvelis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBX-1400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
X-4P001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Primary Immune Deficiency (PID) - Dormant Projects
Primary Immune Deficiency (PID) - Product Development Milestones
Featured News & Press Releases
Nov 22, 2017: Prometic Reports Positive Interim Clinical Data from Ongoing Intravenous Immunoglobulin (IVIG) Pivotal Phase 3 Trial
Nov 06, 2017: Shire to Present New Data on the Treatment of Primary Immunodeficiency
Oct 23, 2017: Shire to Present New Data on Immune Globulin Research at ACAAI 2017 Annual Scientific Meeting
Nov 23, 2016: Green Cross Receives Complete Response Letter from US FDA for IVIG-SN
Sep 23, 2016: Shire to showcase data on HyQvia during European Society for Immunodeficiencies Biennial Meeting
Aug 09, 2016: ProMetic Completes Adult Patients Enrolment in Pivotal IVIG Phase 3 Clinical Trial
Jul 21, 2016: Shire Launches Pediatric Indication for Immunodeficiency Treatment HyQvia in Europe
May 02, 2016: Baxalta Receives Positive Opinion from Europe’s CHMP for HYQVIA to Treat Pediatric Patients
Mar 07, 2016: Green Cross Biotherapeutics Receives Health Canada Approval for Phase III Clinical Trials of IVIG 10%
Mar 03, 2016: Baxalta to present on HYQVIA at 2016 American Academy of Allergy, Asthma & Immunology Annual Meeting
Jan 25, 2016: US FDA Accepts Green Cross' Biologics License Application for IVIG-SN
Dec 02, 2015: Baxalta Receives CHMP Positive Opinion on HYQVIA
Nov 24, 2015: Green Cross Submits Biologics License Application to US FDA for IVIG-SN
Oct 26, 2015: Prometic’s IVIG IND Cleared By FDA
Aug 03, 2015: Baxalta Announces Expanded CMS Coverage for Medicare PI Patients to Receive At-Home Treatment with HYQVIA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Figures
Number of Products under Development for Primary Immune Deficiency (PID), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

List of Tables
Number of Products under Development for Primary Immune Deficiency (PID), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Primary Immune Deficiency (PID) - Pipeline by ADMA Biologics Inc, H1 2018
Primary Immune Deficiency (PID) - Pipeline by Biotest AG, H1 2018
Primary Immune Deficiency (PID) - Pipeline by Casebia Therapeutics, H1 2018
Primary Immune Deficiency (PID) - Pipeline by Genethon SA, H1 2018
Primary Immune Deficiency (PID) - Pipeline by GigaGen Inc, H1 2018
Primary Immune Deficiency (PID) - Pipeline by GlaxoSmithKline Plc, H1 2018
Primary Immune Deficiency (PID) - Pipeline by Green Cross Corp, H1 2018
Primary Immune Deficiency (PID) - Pipeline by Leadiant Biosciences Inc, H1 2018
Primary Immune Deficiency (PID) - Pipeline by Novartis AG, H1 2018
Primary Immune Deficiency (PID) - Pipeline by Octapharma AG, H1 2018
Primary Immune Deficiency (PID) - Pipeline by ProMetic Life Sciences Inc, H1 2018
Primary Immune Deficiency (PID) - Pipeline by Sangamo Therapeutics Inc, H1 2018
Primary Immune Deficiency (PID) - Pipeline by Shire Plc, H1 2018
Primary Immune Deficiency (PID) - Pipeline by Taiga Biotechnologies Inc, H1 2018
Primary Immune Deficiency (PID) - Pipeline by Therapure Biopharma Inc, H1 2018
Primary Immune Deficiency (PID) - Pipeline by UCB SA, H1 2018
Primary Immune Deficiency (PID) - Pipeline by X4 Pharmaceuticals Inc, H1 2018
Primary Immune Deficiency (PID) - Dormant Projects, H1 2018
Loading....